OBJECTIVE:Depressive symptoms are highly relevant for the quality of life, health behavior, and prognosis in patients with coronary artery disease (CAD). However, previous psychotherapy trials in depressed CAD patients produced small to moderate effects on depression, and null effects on cardiac events. In this multicentre psychotherapy trial, symptoms of depression are treated together with the Type D pattern (negative affectivity and social inhibition) in a stepwise approach. METHODS:Men and women (N=569, age 18-75 years) with any manifestation of CAD and depression scores ≥ 8 on the Hospital Anxiety and Depression Scale (HADS), will be randomized (allocation ratio 1:1) into the intervention or control group. Patients with severe heart failure, acutely life-threatening conditions, chronic inflammatory disease, severe depressive episodes or other severe mental illness are excluded. Both groups receive usual medical care. Patients in the intervention group receive three initial sessions of supportive individual psychotherapy. After re-evaluation of depression (weeks 4-8), patients with persisting symptoms receive an additional 25 sessions of combined psychodynamic and cognitive-behavioral group therapy. The control group receives one psychosocial counseling session. Primary efficacy variable is the change of depressive symptoms (HADS) from baseline to 18 months. Secondary endpoints include cardiac events, remission of depressive disorder (SCID) and Type D pattern, health-related quality of life, cardiovascular risk profile, neuroendocrine and immunological activation, heart rate variability, and health care utilization, up to 24 months of follow-up (ISRCTN: 76240576; NCT00705965). Funded by the German Research Foundation.
RCT Entities:
OBJECTIVE:Depressive symptoms are highly relevant for the quality of life, health behavior, and prognosis in patients with coronary artery disease (CAD). However, previous psychotherapy trials in depressed CADpatients produced small to moderate effects on depression, and null effects on cardiac events. In this multicentre psychotherapy trial, symptoms of depression are treated together with the Type D pattern (negative affectivity and social inhibition) in a stepwise approach. METHODS:Men and women (N=569, age 18-75 years) with any manifestation of CAD and depression scores ≥ 8 on the Hospital Anxiety and Depression Scale (HADS), will be randomized (allocation ratio 1:1) into the intervention or control group. Patients with severe heart failure, acutely life-threatening conditions, chronic inflammatory disease, severe depressive episodes or other severe mental illness are excluded. Both groups receive usual medical care. Patients in the intervention group receive three initial sessions of supportive individual psychotherapy. After re-evaluation of depression (weeks 4-8), patients with persisting symptoms receive an additional 25 sessions of combined psychodynamic and cognitive-behavioral group therapy. The control group receives one psychosocial counseling session. Primary efficacy variable is the change of depressive symptoms (HADS) from baseline to 18 months. Secondary endpoints include cardiac events, remission of depressive disorder (SCID) and Type D pattern, health-related quality of life, cardiovascular risk profile, neuroendocrine and immunological activation, heart rate variability, and health care utilization, up to 24 months of follow-up (ISRCTN: 76240576; NCT00705965). Funded by the German Research Foundation.
Authors: Suzanne H Richards; Lindsey Anderson; Caroline E Jenkinson; Ben Whalley; Karen Rees; Philippa Davies; Paul Bennett; Zulian Liu; Robert West; David R Thompson; Rod S Taylor Journal: Cochrane Database Syst Rev Date: 2017-04-28
Authors: Thomas Meyer; Isabel Rothe; Julia Staab; Hans-Christian Deter; Stella V Fangauf; Stefanie Hamacher; Martin Hellmich; Jana Jünger; Karl-Heinz Ladwig; Matthias Michal; Katja Petrowski; Joram Ronel; Wolfgang Söllner; Cora Weber; Martina de Zwaan; Redford B Williams; Christian Albus; Christoph Herrmann-Lingen Journal: Biochem Genet Date: 2020-05-05 Impact factor: 1.890
Authors: Frank Vitinius; Steffen Escherich; Hans-Christian Deter; Martin Hellmich; Jana Jünger; Katja Petrowski; Karl-Heinz Ladwig; Frank Lambertus; Matthias Michal; Cora Weber; Martina de Zwaan; Christoph Herrmann-Lingen; Joram Ronel; Christian Albus Journal: BMC Psychiatry Date: 2019-02-04 Impact factor: 3.630
Authors: Karl-Heinz Ladwig; Florian Lederbogen; Christian Albus; Christiane Angermann; Martin Borggrefe; Denise Fischer; Kurt Fritzsche; Markus Haass; Jochen Jordan; Jana Jünger; Ingrid Kindermann; Volker Köllner; Bernhard Kuhn; Martin Scherer; Melchior Seyfarth; Heinz Völler; Christiane Waller; Christoph Herrmann-Lingen Journal: Ger Med Sci Date: 2014-05-07